ArticleProteomics. Clinical applications2012
Plasma proteomics of differential outcome to long-term therapy in children with idiopathic pulmonary arterial hypertension.
Article in Proteomics. Clinical applications, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- SAA4: An Underdog Within the Serum Amyloid a Superfamily?International journal of molecular sciences · 2026Review
- New perspectives in the management of adults with congenital heart disease: insights from the 2025 ACHD Congress.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Embracing the challenges of neonatal and paediatric pulmonary hypertension.The European respiratory journal · 2024Review
- Prognostic biomarkers in pediatric pulmonary arterial hypertension.Cardiovascular diagnosis and therapy · 2021Review
- Metalloproteinases and their inhibitors are associated with pulmonary arterial stiffness and ventricular function in pediatric pulmonary hypertension.American journal of physiology. Heart and circulatory physiology · 2021Article
- Proteomic analysis of pulmonary arterial hypertension.Therapeutic advances in chronic disease · 2021Review
- Diagnosis, Evaluation and Treatment of Pulmonary Arterial Hypertension in Children.Children (Basel, Switzerland) · 2018Review
- Update on novel targets and potential treatment avenues in pulmonary hypertension.American journal of physiology. Lung cellular and molecular physiology · 2016Review
- Pulmonary Hypertension in Children.Cardiology clinics · 2016Review
- Article
- Erythropoietin upregulation in pulmonary arterial hypertension.Pulmonary circulation · 2014Article
- Biomarkers for pediatric pulmonary arterial hypertension - a call to collaborate.Frontiers in pediatrics · 2014Review
- Current challenges in pediatric pulmonary hypertension.Seminars in respiratory and critical care medicine · 2013Review
- Clinical trials in neonates and children: Report of the pulmonary hypertension academic research consortium pediatric advisory committee.Pulmonary circulation · 2013Article
- Phosphoproteomic analysis of lung tissue from patients with pulmonary arterial hypertension.Pulmonary circulationArticle
- Serum biomarker analysis at the protein level on pulmonary hypertension secondary to old anterior myocardial infarction.Pulmonary circulationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
purposeThe prognosis for children with IPAH unresponsive to therapy is poor. We investigated the plasma proteome for a molecular basis of good versus poor outcome to long-term vasodilator therapy. EXPERIMENTAL
designPlasma was collected at baseline or shortly after therapy initiation and following chronic vasodilator therapy, then divided into those with good outcome (n = 8), and those with a poor outcome (n = 7). To identify proteins unique to either outcome, we used differential gel electrophoresis and mass spectrometry. Results were confirmed by commercial enzyme-linked immunosorbent assay.
resultsBefore and after therapy, SAA-4 was 4-fold lower in those with good outcome compared to those with poor outcome, while serum paraoxonase/arylesterase-1 was increased 2-fold in those with good outcome versus poor outcome. After therapy, haptoglobin and hemopexin were 1.45- and 1.8-fold lower, respectively, in those with a good versus poor outcome. Among those with a good outcome, SAP was 1.3-fold lower prior to therapy. CONCLUSIONS AND CLINICAL RELEVANCE: SAP and SAA-4 regulate circulating mononuclear phagocytes. As such, they may contribute to the differential response to chronic vasodilator therapy in the context of inflammation in IPAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.